Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,536 JPY | +0.72% | +0.72% | -34.63% |
Apr. 05 | Menicon Establishes German Subsidiary and Alters Capital Increase Payment Timing | MT |
Apr. 04 | Menicon Buys French Specialty Contact Lens Maker Dencott | MT |
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.63% | 745M | B- | ||
+13.38% | 100B | B | ||
+12.13% | 40.03B | B | ||
+0.16% | 18.83B | B- | ||
-14.13% | 2.41B | D+ | ||
+4.89% | 1.76B | C+ | ||
+24.59% | 1.19B | - | ||
-34.19% | 765M | - | ||
-6.50% | 676M | - | ||
+22.63% | 490M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 7780 Stock
- Ratings Menicon Co., Ltd.